CIGB-552

OC(C=C1)=CC=C1C[C@@H](C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@H](C(N[C@H](C(O)=O)CC2=CNC3=CC=CC=C23)=O)CC4=CC=CC=C4)=O)=O)=O)=O)NC([C@H](CCCCN)NC([C@@H](NC([C@H](CCCCN)NC([C@@H](CC(C)C)NC([C@H](CCCNC(N)=N)NC([C@H](CCCNC(N)=N)NC([C@@H](NC([C@H]([C@H](O)C)NC([C@@H]5N(CCC5)C([C@H](CCCCN)NC([C@H]([C@@H](C)CC)NC([C@H](CCCNC(N)=N)NC([C@H](C)NC([C@@H](NC(C)=O)CC6=CN=CN6)=O)=O)=O)=O)=O)=O)=O)CC7=CC=CC=C7)=O)=O)=O)=O)=O)CC8=CNC9=CC=CC=C89)=O)=O

[1]Fernández Massó JR, et al. The Antitumor Peptide CIGB-552 Increases COMMD1 and Inhibits Growth of Human Lung Cancer Cells. J Amino Acids. 2013;2013:251398. |[2]Gomez Rodriguez Y, et al. Synergic effect of anticancer peptide CIGB-552 and Cisplatin in lung cancer models. Mol Biol Rep. 2022 Apr;49 (4) :3197-3212.|[3]Daghero H, et al. The Anticancer Peptide CIGB-552 Exerts Anti-Inflammatory and Anti-Angiogenic Effects through COMMD1. Molecules. 2020 Dec 31;26 (1) :152.|[4]Vallespí MG, et al. Antitumor efficacy, pharmacokinetic and biodistribution studies of the anticancer peptide CIGB-552 in mouse models. J Pept Sci. 2014 Nov;20 (11) :850-9.